trans-2-amino-1,3,4-trihydroxy-octadec-8-en | 81520-97-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trans-2-amino-1,3,4-trihydroxy-octadec-8-en
• 英文别名: Dehydrophytosphingosine (not validated, isomer of 1677)；(E)-2-aminooctadec-8-ene-1,3,4-triol
• CAS: 81520-97-0
• 化学式: C₁₈H₃₇NO₃
• 分子量: 315.497
• InChiKey: CQKNELOTFUSOTP-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  86.7
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  trans-2-amino-1,3,4-trihydroxy-octadec-8-en 以 四氢呋喃 、 甲醇 为溶剂， 反应 12.0h， 生成 N-((E)-2,3-Bis-trimethylsilanyloxy-1-trimethylsilanyloxymethyl-heptadec-7-enyl)-acetamide
  参考文献：
  名称：

  Kraus, Rupert; Spiteller, Gerhard, Liebigs Annalen der Chemie, 1991, # 2, p. 125 - 128

  摘要：

  DOI：
• 作为产物：
  描述：

  N-[(E)-1,3,4-trihydroxyoctadec-8-en-2-yl]icosanamide 、 水 、 盐酸 、 甲醇 生成 trans-2-amino-1,3,4-trihydroxy-octadec-8-en
  参考文献：
  名称：

  KRAUS, RUPERT;SPITELLER, GERHARD, LIEBIGS ANN. CHEM. ,(1991) N, C. 125-128

  摘要：

  DOI：

文献信息

• Sphingoid compounds for prophylaxis and/or therapy of a viral infection
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US10688065B2

  公开（公告）日：2020-06-23

  Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

  本文提供了预防或治疗受试者病毒感染的方法。某些方面提供了向人等受试者施用鞘氨醇化合物（可选鞘氨醇）、激活生成鞘氨醇基（可选鞘氨醇）的活性成分；或抑制鞘氨醇基（可选鞘氨醇）降解的活性剂。通过增加施用组合物的受试者或受试者的局部（如鼻子或鼻子内部或其部分）的鞘氨醇浓度，可降低病毒感染受试者或其细胞的能力，从而达到预防病毒感染的目的。
• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。
• Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：US11298412B2

  公开（公告）日：2022-04-12

  Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the airways, nose or interior of the nose or portion thereof, the ability or SARS-CoV-2 to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

  本文提供了预防或治疗 SARS-CoV-2 感染的方法。某些方面提供了对人等受试者施用鞘氨醇化合物（可选鞘氨醇）、激活鞘氨醇基（可选鞘氨醇）生成的活性成分；或抑制鞘氨醇基（可选鞘氨醇）降解的活性剂。通过增加受试者或受试者施用组合物的部位（如呼吸道、鼻腔或鼻腔内部或其部分）的鞘氨醇的局部浓度，可降低 SARS-CoV-2 感染受试者或其细胞的能力，从而起到预防病毒感染的作用。
• KRAUS, RUPERT;SPITELLER, GERHARD, LIEBIGS ANN. CHEM. ,(1991) N, C. 125-128
  作者：KRAUS, RUPERT、SPITELLER, GERHARD

  DOI：——

  日期：——
• SPHINGOID COMPOUNDS FOR USE IN THE PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION
  申请人：Harbins Ruhr Bioscience, Inc.

  公开号：EP3863616A2

  公开（公告）日：2021-08-18